organic halide salt - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	organic halide salt	go back to main search page
Accession:	CHEBI:51069	browse the term
Synonyms:	related_synonym:	organic halide salts

show annotations for term's descendants Sort by:
Rat (1163) Mouse (1187) Human (1217) Chinchilla (0) Bonobo (0) Dog (5) Squirrel (0) Pig (7) Green Monkey (0) Naked Mole-rat (0) All
Genes (1163)

(1R,3S)-3-(adamantan-1-yl)-1-(aminomethyl)-3,4-dihydroisochromene-5,6-diol hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dopamine receptor D1

multiple interactions
affects localization

A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein]

NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002

(S)-duloxetine hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

androgen receptor

multiple interactions

Duloxetine Hydrochloride binds to and results in decreased activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

Cd48 molecule

multiple interactions

Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of CD48 protein]

NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases activity
multiple interactions

Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein
Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Duloxetine Hydrochloride results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Duloxetine Hydrochloride results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

heme oxygenase 1

increases expression

Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 1 alpha

multiple interactions

Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in increased expression of IL1A protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Duloxetine Hydrochloride results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium inwardly-rectifying channel, subfamily J, member 5

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]

NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518

G

potassium inwardly-rectifying channel, subfamily J, member 6

multiple interactions

Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA]

NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758

G

NFE2 like bZIP transcription factor 2

affects localization

Duloxetine Hydrochloride affects the localization of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

prolactin

increases expression

Duloxetine Hydrochloride results in increased expression of PRL protein

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

vascular endothelial growth factor A

multiple interactions

Duloxetine Hydrochloride inhibits the reaction [Indomethacin results in decreased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

1,1-dimethyl-4-phenylpiperazinium iodide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding competes with [Epibatidine binds to Chrna2 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 3 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding [Epibatidine binds to Chrna3 protein]

CTD
RGD

PMID:9454827 PMID:15016836

NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrna4 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrna4 protein]

CTD
RGD

PMID:9454827 PMID:14645658 PMID:15016836

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions
increases response to substance
increases activity

Dimethylphenylpiperazinium Iodide inhibits the reaction [Bungarotoxins binds to CHRNA7 protein]
CHRNA7 protein mutant form results in increased susceptibility to Dimethylphenylpiperazinium Iodide
Dimethylphenylpiperazinium Iodide results in increased activity of CHRNA7 protein

PMID:10082212 PMID:10216184

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]
1,1-dimethyl-4-phenylpiperazinium iodide affects binding to Chrnb2 protein; 1,1-dimethyl-4-phenylpiperazinium iodide competes with [Epibatidine binds to Chrnb2 protein]

CTD
RGD

PMID:14645658 PMID:15016836

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

cholinergic receptor nicotinic beta 4 subunit

multiple interactions

Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA2 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA3 protein]; Dimethylphenylpiperazinium Iodide results in increased activity of [CHRNB4 protein binds to CHRNA4 protein]

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

tumor necrosis factor

increases activity

TNF results in increased activity of Dimethylphenylpiperazinium Iodide

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

thiazolyl blue results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

aconitase 2

multiple interactions

[Calcium results in increased activity of ACO2 protein] which results in increased reduction of thiazolyl blue; [Potassium deficiency results in decreased activity of ACO2 protein] which results in decreased reduction of thiazolyl blue

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

caspase 3

increases activity

thiazolyl blue results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

thiazolyl blue results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases reduction
multiple interactions

NQO2 protein results in increased reduction of thiazolyl blue
resveratrol inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]; Tacrine inhibits the reaction [NQO2 protein results in increased reduction of thiazolyl blue]

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

3beta-(2-diethylaminoethoxy)androst-5-en-17-one hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glypican 1

decreases degradation

3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one results in decreased degradation of GPC1 protein

NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047

G

interleukin 1 beta

multiple interactions

3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one inhibits the reaction [[Lipopolysaccharides results in increased susceptibility to Silicon Dioxide] which results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

4-fluoro-N-\{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl\}benzamide hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

5-hydroxytryptamine receptor 1A

multiple interactions

[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine]

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

acridine orange

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

increases response to substance

BAX protein results in increased susceptibility to Acridine Orange

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

glutathione S-transferase pi 1

multiple interactions

[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

tumor protein p53

multiple interactions

Acridine Orange results in increased stability of and results in increased activity of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

ambenonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

Ambenonium Chloride results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

amyloid beta precursor protein

affects cleavage

Ambenonium Chloride affects the cleavage of APP protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

amprolium

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 19 member 3

multiple interactions

Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Amprolium inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine]

NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337

atomoxetine hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases hydroxylation
multiple interactions
increases metabolic processing

CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride
Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Atomoxetine Hydrochloride]

PMID:17470523 PMID:34431675

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

auramine O

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions
increases expression

ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]
Benzophenoneidum results in increased expression of ALDH1A1 protein

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

anoctamin 6

increases expression

Benzophenoneidum results in increased expression of ANO6 protein

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589

G

A-Raf proto-oncogene, serine/threonine kinase

increases expression

Benzophenoneidum results in increased expression of ARAF protein

NCBI chr X:1,227,392...1,292,356
Ensembl chr X:1,227,392...1,239,073

G

ATPase H+ transporting accessory protein 2

increases expression

Benzophenoneidum results in increased expression of ATP6AP2 protein

NCBI chr X:10,183,983...10,210,948
Ensembl chr X:10,183,068...10,210,918

G

coiled-coil domain containing 22

increases expression

Benzophenoneidum results in increased expression of CCDC22 protein

NCBI chr X:14,898,296...14,910,244
Ensembl chr X:14,898,296...14,910,244

G

coiled-coil domain 39 molecular ruler complex subunit

increases expression

Benzophenoneidum results in increased expression of CCDC39 protein

NCBI chr 2:116,665,651...116,703,354
Ensembl chr 2:116,665,261...116,703,350

G

CD44 molecule

increases expression

Benzophenoneidum results in increased expression of CD44 protein

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

chromosome transmission fidelity factor 18

increases expression

Benzophenoneidum results in increased expression of CHTF18 protein

NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050

G

copper metabolism domain containing 1

increases expression

Benzophenoneidum results in increased expression of COMMD1 protein

NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501

G

COP9 signalosome subunit 7B

increases expression

Benzophenoneidum results in increased expression of COPS7B protein

NCBI chr 9:87,238,132...87,263,967
Ensembl chr 9:87,238,375...87,263,967

G

cullin 3

increases expression

Benzophenoneidum results in increased expression of CUL3 protein

NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462

G

dynein light chain Tctex-type 1

increases expression

Benzophenoneidum results in increased expression of DYNLT1 protein

NCBI chr 1:46,887,017...46,893,956
Ensembl chr 1:46,887,017...46,893,881

G

eukaryotic translation initiation factor 4 gamma, 3

increases expression

Benzophenoneidum results in increased expression of EIF4G3 protein

NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363

G

FAST kinase domains 2

increases expression

Benzophenoneidum results in increased expression of FASTKD2 protein

NCBI chr 9:65,166,148...65,188,184
Ensembl chr 9:65,168,228...65,188,174

G

H2A.X variant histone

increases phosphorylation

Benzophenoneidum results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hook microtubule-tethering protein 3

increases expression

Benzophenoneidum results in increased expression of HOOK3 protein

NCBI chr16:65,954,293...66,058,812
Ensembl chr16:65,954,350...66,061,338

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Benzophenoneidum results in increased expression of HSD17B7 protein

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

huntingtin

increases expression

Benzophenoneidum results in increased expression of HTT protein

NCBI chr14:75,845,836...75,996,094
Ensembl chr14:75,845,836...75,995,070

G

IQ motif containing GTPase activating protein 3

increases expression

Benzophenoneidum results in increased expression of IQGAP3 protein

NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956

G

kinesin-associated protein 3

increases expression

Benzophenoneidum results in increased expression of KIFAP3 protein

NCBI chr13:76,127,702...76,264,654
Ensembl chr13:76,127,696...76,264,650

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase kinase 4

increases expression

Benzophenoneidum results in increased expression of MAP2K4 protein

NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993

G

methyl-CpG binding domain protein 3

increases expression

Benzophenoneidum results in increased expression of MBD3 protein

NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165

G

marker of proliferation Ki-67

increases expression

Benzophenoneidum results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

nitric oxide associated 1

increases expression

Benzophenoneidum results in increased expression of NOA1 protein

NCBI chr14:30,835,264...30,851,294
Ensembl chr14:30,835,247...30,851,293

G

nucleoporin 62

increases expression

Benzophenoneidum results in increased expression of NUP62 protein

NCBI chr 1:95,298,995...95,314,902
Ensembl chr 1:95,295,526...95,315,174

G

phospholipase C, gamma 1

increases expression

Benzophenoneidum results in increased expression of PLCG1 protein

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

protein phosphatase 4, regulatory subunit 1

increases expression

Benzophenoneidum results in increased expression of PPP4R1 protein

NCBI chr 9:105,391,271...105,450,626
Ensembl chr 9:105,391,412...105,450,633

G

DNA primase subunit 2

increases expression

Benzophenoneidum results in increased expression of PRIM2 protein

NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030

G

prominin 1

increases expression

Benzophenoneidum results in increased expression of PROM1 protein

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

protein only RNase P catalytic subunit

increases expression

Benzophenoneidum results in increased expression of PRORP protein

NCBI chr 6:72,669,659...72,762,419
Ensembl chr 6:72,670,847...72,762,416

G

serine hydroxymethyltransferase 1

increases expression

Benzophenoneidum results in increased expression of SHMT1 protein

NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820

G

serine and arginine rich splicing factor 11

increases expression

Benzophenoneidum results in increased expression of SRSF11 protein

NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425

G

TBC1 domain family, member 15

increases expression

Benzophenoneidum results in increased expression of TBC1D15 protein

NCBI chr 7:50,804,553...50,860,272
Ensembl chr 7:50,804,012...50,860,175

G

transcription factor A, mitochondrial

increases expression

Benzophenoneidum results in increased expression of TFAM protein

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

ubiquitin specific peptidase 24

increases expression

Benzophenoneidum results in increased expression of USP24 protein

NCBI chr 5:121,080,687...121,210,321
Ensembl chr 5:121,080,470...121,210,311

G

WASH complex subunit 5

increases expression

Benzophenoneidum results in increased expression of WASHC5 protein

NCBI chr 7:90,884,192...90,936,096
Ensembl chr 7:90,884,197...90,936,103

azure A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutamic--pyruvic transaminase

increases activity

Azure A results in increased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

azure B

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

amyloid beta precursor protein

multiple interactions

[Azure B affects the cleavage of APP protein] which results in decreased secretion of APP protein modified form; Azure B results in decreased expression of and affects the cleavage of APP protein

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

beta-secretase 1

decreases activity

Azure B results in decreased activity of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

benzalkonium chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

Benzalkonium Compounds results in increased expression of AACS mRNA

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

ATP binding cassette subfamily A member 1

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 12

increases expression

Benzalkonium Compounds results in increased expression of ABCA12 mRNA

NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049

G

ATP binding cassette subfamily A member 6

decreases expression

Benzalkonium Compounds results in decreased expression of ABCA6 mRNA

NCBI chr10:95,142,805...95,212,087
Ensembl chr10:95,142,966...95,211,530

G

aconitate decarboxylase 1

increases expression

Benzalkonium Compounds results in increased expression of ACOD1 mRNA

NCBI chr15:79,871,819...79,881,101
Ensembl chr15:79,871,827...79,880,529

G

acid phosphatase 6, lysophosphatidic

increases expression

Benzalkonium Compounds results in increased expression of ACP6 mRNA

NCBI chr 2:184,711,975...184,733,067
Ensembl chr 2:184,711,619...184,733,017

G

acyl-CoA synthetase long-chain family member 4

increases expression

Benzalkonium Compounds results in increased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

adenosine deaminase

increases expression

Benzalkonium Compounds results in increased expression of ADA mRNA

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

decreases expression

Benzalkonium Compounds results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

adenosine A1 receptor

decreases expression

Benzalkonium Compounds results in decreased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

adrenoceptor alpha 2A

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

angiotensin II receptor, type 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

aldo-keto reductase family 1 member B10

increases expression

Benzalkonium Compounds results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

albumin

decreases expression

Benzalkonium Compounds results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

adhesion molecule with Ig like domain 2

increases expression

Benzalkonium Compounds results in increased expression of AMIGO2 mRNA

NCBI chr 7:128,391,493...128,394,589
Ensembl chr 7:128,390,412...128,394,695

G

apolipoprotein A1

decreases expression

Benzalkonium Compounds results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Benzalkonium Compounds results in decreased expression of APOA2 mRNA

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein C1

decreases expression

Benzalkonium Compounds results in decreased expression of APOC1 mRNA

NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375

G

aquaporin 3 (Gill blood group)

increases expression

Benzalkonium Compounds results in increased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

amphiregulin

increases expression

Benzalkonium Compounds results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arginase 2

increases expression

Benzalkonium Compounds results in increased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

ADP-ribosyltransferase 3

decreases expression

Benzalkonium Compounds results in decreased expression of ART3 mRNA

NCBI chr14:15,637,230...15,719,442
Ensembl chr14:15,637,237...15,665,407

G

activating transcription factor 4

decreases expression

Benzalkonium Compounds results in decreased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

ATP synthase F1 subunit epsilon

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5F1E mRNA

NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase membrane subunit G

decreases expression

Benzalkonium Compounds results in decreased expression of ATP5MG mRNA

NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559

G

Beta-1,3-galactosyltransferase 4

affects response to substance

B3GALT4 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,936,089...4,937,664
Ensembl chr20:4,931,768...4,938,315

G

BMP and activin membrane-bound inhibitor

increases expression

Benzalkonium Compounds results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BCL3, transcription coactivator

increases expression

Benzalkonium Compounds results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

betacellulin

decreases expression

Benzalkonium Compounds results in decreased expression of BTC mRNA

NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049

G

complement C3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

caspase 3

increases cleavage
multiple interactions

Benzalkonium Compounds analog results in increased cleavage of CASP3 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

decreases expression

Benzalkonium Compounds results in decreased expression of CASP8 mRNA

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

C-C motif chemokine ligand 11

increases expression

Benzalkonium Compounds results in increased expression of CCL11 protein

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

increases expression
increases secretion

Benzalkonium Compounds results in increased expression of CCL2 mRNA; Benzalkonium Compounds results in increased expression of CCL2 protein
Benzalkonium Compounds results in increased secretion of CCL2 protein

PMID:30171875 PMID:30517752 PMID:31707104

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Benzalkonium Compounds results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 24

decreases expression

Benzalkonium Compounds results in decreased expression of CCL24 mRNA

NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CCL3 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein

PMID:30517752 PMID:31158415

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

decreases expression
multiple interactions
increases expression

Benzalkonium Compounds results in decreased expression of CCL4 mRNA; Benzalkonium Compounds results in decreased expression of CCL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein
Benzalkonium Compounds results in increased expression of CCL4 protein

PMID:18353026 PMID:20713136 PMID:30517752 PMID:31158415

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

increases expression

Benzalkonium Compounds results in increased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

increases expression

Benzalkonium Compounds results in increased expression of CCL7 mRNA; Benzalkonium Compounds results in increased expression of CCL7 protein

PMID:30171875 PMID:30517752

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

cellular communication network factor 2

decreases expression

Benzalkonium Compounds results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cellular communication network factor 3

increases expression

Benzalkonium Compounds results in increased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019

G

C-C motif chemokine receptor 4

decreases expression

Benzalkonium Compounds results in decreased expression of CCR4 mRNA

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

increases expression

Benzalkonium Compounds results in increased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

CD177 molecule

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA

NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621

G

CD274 molecule

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

CD300C molecule 2

increases expression

Benzalkonium Compounds results in increased expression of CD300C2 mRNA

NCBI chr10:100,253,312...100,258,553
Ensembl chr10:100,253,624...100,258,323

G

cell division cycle 6

multiple interactions
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Benzalkonium Compounds results in decreased expression of CDC6 protein]
Benzalkonium Compounds results in decreased expression of CDC6 mRNA; Benzalkonium Compounds results in decreased expression of CDC6 protein

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cilia and flagella associated protein 61

increases expression

Benzalkonium Compounds results in increased expression of CFAP61 mRNA

NCBI chr 3:133,354,400...133,633,310
Ensembl chr 3:133,354,197...133,633,320

G

complement factor D

decreases expression

Benzalkonium Compounds results in decreased expression of CFD mRNA

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

chitinase 3 like 1

increases expression

Benzalkonium Compounds results in increased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

cholinergic receptor nicotinic beta 4 subunit

decreases expression

Benzalkonium Compounds results in decreased expression of CHRNB4 mRNA

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

CIMAP1 family member D

decreases expression

Benzalkonium Compounds results in decreased expression of CIMAP1D mRNA

NCBI chr 7:10,049,472...10,065,626
Ensembl chr 7:10,059,589...10,065,125

G

cardiotrophin-like cytokine factor 1

increases expression

Benzalkonium Compounds results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

cornifelin

increases expression

Benzalkonium Compounds results in increased expression of CNFN mRNA; Benzalkonium Compounds results in increased expression of CNFN protein

NCBI chr 1:80,949,699...80,953,747
Ensembl chr 1:80,951,600...80,953,747

G

colony stimulating factor 1

increases expression

Benzalkonium Compounds results in increased expression of CSF1 protein

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

increases expression

Benzalkonium Compounds results in increased expression of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 3

increases expression

Benzalkonium Compounds results in increased expression of CSF3 protein

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

CTP synthase 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180

G

C-X-C motif chemokine ligand 10

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL10 mRNA; Benzalkonium Compounds results in increased expression of CXCL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein

PMID:23445166 PMID:30517752 PMID:31158415

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of CXCL2 mRNA; Benzalkonium Compounds results in increased expression of CXCL2 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein

PMID:30171875 PMID:30517752 PMID:31158415

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA
Benzalkonium Compounds results in increased expression of CXCL1 protein; Benzalkonium Compounds results in increased expression of CXCL3 mRNA

PMID:30171875 PMID:30517752

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine receptor 1

increases expression

Benzalkonium Compounds results in increased expression of CXCR1 mRNA

NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084

G

C-X-C motif chemokine receptor 4

increases expression

Benzalkonium Compounds results in increased expression of CXCR4 mRNA

NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases expression
increases expression

Benzalkonium Compounds results in decreased expression of CYP1A1 mRNA
Benzalkonium Compounds results in increased expression of CYP1A1 mRNA

PMID:20713136 PMID:30806763

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Benzalkonium Compounds results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 51

increases expression

Benzalkonium Compounds results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

DNA-damage inducible transcript 3

increases expression

Benzalkonium Compounds results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

24-dehydrocholesterol reductase

increases expression

Benzalkonium Compounds results in increased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

decreases activity
increases expression

Benzalkonium Compounds results in decreased activity of DHCR7 protein
Benzalkonium Compounds results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

iodothyronine deiodinase 1

decreases activity

Benzalkonium Compounds results in decreased activity of DIO1 protein

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

iodothyronine deiodinase 2

decreases activity

Benzalkonium Compounds results in decreased activity of DIO2 protein

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

decreases activity

Benzalkonium Compounds results in decreased activity of DIO3 protein

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

delta like non-canonical Notch ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

dual specificity phosphatase 1

increases expression

Benzalkonium Compounds results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 10

increases expression

Benzalkonium Compounds results in increased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716

G

EBP, cholestenol delta-isomerase

increases expression

Benzalkonium Compounds results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

epidermal growth factor

decreases expression

Benzalkonium Compounds results in decreased expression of EGF mRNA

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 1

increases expression

Benzalkonium Compounds results in increased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

E74 like ETS transcription factor 3

increases expression

Benzalkonium Compounds results in increased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

ELOVL fatty acid elongase 1

increases expression

Benzalkonium Compounds results in increased expression of ELOVL1 mRNA

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ELOVL fatty acid elongase 6

increases expression

Benzalkonium Compounds results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

endonuclease, poly(U)-specific

increases expression

Benzalkonium Compounds results in increased expression of ENDOU mRNA

NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596

G

enolase 1

decreases expression

Benzalkonium Compounds results in decreased expression of ENO1 mRNA

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
Ensembl chr 3:160,719,951...160,731,336

G

ethanolamine kinase 1

increases expression

Benzalkonium Compounds results in increased expression of ETNK1 mRNA

NCBI chr 4:176,126,056...176,170,325
Ensembl chr 4:176,126,180...176,193,770

G

exonuclease 1

increases expression

Benzalkonium Compounds results in increased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

ezrin

increases expression

Benzalkonium Compounds results in increased expression of EZR mRNA; Benzalkonium Compounds results in increased expression of EZR protein

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

family with sequence similarity 83, member A

increases expression

Benzalkonium Compounds results in increased expression of FAM83A mRNA

NCBI chr 7:89,522,826...89,547,284
Ensembl chr 7:89,522,826...89,547,388

G

fibroblast growth factor 2

affects response to substance

FGF2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

FGR proto-oncogene, Src family tyrosine kinase

increases expression

Benzalkonium Compounds results in increased expression of FGR mRNA

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

filaggrin

increases expression

Benzalkonium Compounds results in increased expression of FLG mRNA

NCBI chr 2:178,884,793...178,912,986

G

forkhead box C1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA

NCBI chr17:32,631,379...32,635,361
Ensembl chr17:32,633,142...32,634,803

G

forkhead box N1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA

NCBI chr10:63,251,400...63,273,710
Ensembl chr10:63,251,400...63,273,710

G

forkhead box P3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

GATA binding protein 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Benzalkonium Compounds results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glutathione peroxidase 2

increases expression

Benzalkonium Compounds results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

heparin-binding EGF-like growth factor

increases expression

Benzalkonium Compounds results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HCK proto-oncogene, Src family tyrosine kinase

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA

NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

Benzalkonium Compounds results in increased expression of HERPUD1 mRNA

NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424

G

hepatocyte growth factor

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

increases expression

Benzalkonium Compounds results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Benzalkonium Compounds results in increased expression of HMGCR mRNA

PMID:26919959 PMID:31199489

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Benzalkonium Compounds results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homeobox A7

decreases expression

Benzalkonium Compounds results in decreased expression of HOXA7 mRNA

NCBI chr 4:81,315,730...81,317,629
Ensembl chr 4:81,314,625...81,317,659

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Benzalkonium Compounds results in increased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 5

decreases expression

Benzalkonium Compounds results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

Benzalkonium Compounds results in increased expression of ICAM1 mRNA; Benzalkonium Compounds results in increased expression of ICAM1 protein

PMID:21742781 PMID:30806763

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inhibitor of DNA binding 1

increases expression

Benzalkonium Compounds results in increased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Benzalkonium Compounds results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon gamma

increases expression

Benzalkonium Compounds results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

multiple interactions
increases expression

Benzalkonium Compounds results in increased expression of and results in decreased secretion of IL10 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein
Benzalkonium Compounds results in increased expression of IL10 protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13 receptor subunit alpha 2

increases expression

Benzalkonium Compounds results in increased expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 15

increases expression

Benzalkonium Compounds results in increased expression of IL15 protein

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820

G

interleukin 17F

increases expression

Benzalkonium Compounds results in increased expression of IL17F mRNA

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 18

increases expression

Benzalkonium Compounds results in increased expression of IL18 protein
Benzalkonium Compounds results in increased expression of IL18 mRNA

PMID:30517752 PMID:30806763

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 alpha

increases secretion
multiple interactions
increases expression

Benzalkonium Compounds results in increased secretion of IL1A protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein
Benzalkonium Compounds results in increased expression of IL1A protein
Benzalkonium Compounds results in increased expression of IL1A mRNA; Benzalkonium Compounds results in increased expression of IL1A protein

PMID:8006454 PMID:12781210 PMID:25290854 PMID:30240708 PMID:30517752 More...

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL1B protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein

PMID:29953848 PMID:30517752 PMID:31158415

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 family member 10

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA

NCBI chr 3:7,072,511...7,075,439
Ensembl chr 3:7,072,511...7,075,439

G

interleukin 23 subunit alpha

increases expression

Benzalkonium Compounds results in increased expression of IL23A mRNA

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 24

increases expression

Benzalkonium Compounds results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 27

increases expression

Benzalkonium Compounds results in increased expression of IL27 protein

NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582

G

interleukin 3

increases expression

Benzalkonium Compounds results in increased expression of IL3 protein

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 31

increases expression

Benzalkonium Compounds results in increased expression of IL31 protein

NCBI chr12:33,095,108...33,105,026
Ensembl chr12:33,092,097...33,105,037

G

interleukin 31 receptor A

decreases expression

Benzalkonium Compounds results in decreased expression of IL31RA mRNA

NCBI chr 2:44,118,748...44,189,943
Ensembl chr 2:44,122,624...44,183,767

G

interleukin 34

decreases expression

Benzalkonium Compounds results in decreased expression of IL34 mRNA

NCBI chr19:38,714,990...38,782,749
Ensembl chr19:38,714,991...38,764,000

G

interleukin 36, alpha

increases expression

Benzalkonium Compounds results in increased expression of IL36A mRNA

NCBI chr 3:6,996,851...7,001,400
Ensembl chr 3:6,996,851...7,001,400

G

interleukin 36, beta

increases expression

Benzalkonium Compounds results in increased expression of IL36B mRNA

NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619

G

interleukin 36, gamma

increases expression

Benzalkonium Compounds results in increased expression of IL36G mRNA

NCBI chr 3:6,948,323...6,954,485
Ensembl chr 3:6,948,297...6,954,480

G

interleukin 4

increases expression
multiple interactions

Benzalkonium Compounds results in increased expression of IL4 protein
[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein

PMID:30517752 PMID:31158415

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

increases expression

Benzalkonium Compounds results in increased expression of IL5 protein

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

increases secretion
multiple interactions
affects response to substance
increases expression

Benzalkonium Compounds results in increased secretion of IL6 protein
[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ADRA2A mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of AGTR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C1S2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of C3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD177 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CD274 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CTPS1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of CXCL5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXC1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXN1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of FOXP3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GATA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of GSDMA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HCK mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of HGF mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IGHA mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of IL1F10 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP16-3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-5 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP19-9B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP6-2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MRGPRA2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SAA3 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SIGLECE mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF26 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA; [IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of IL6 mRNA; Benzalkonium Compounds results in increased expression of IL6 protein
Benzalkonium Compounds results in increased expression of and results in increased secretion of IL6 protein

PMID:17763283 PMID:28214551 PMID:29953848 PMID:30171875 PMID:30517752 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

interleukin 6 receptor

multiple interactions
increases response to substance

[IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in decreased expression of IL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL3 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CCL4 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL10 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of CXCL2 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1A protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL1B protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL22 protein; [IL6RA gene mutant form results in increased susceptibility to Benzalkonium Compounds] which results in increased expression of IL6 protein

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

interleukin 7 receptor

increases expression

Benzalkonium Compounds results in increased expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

inhibin subunit beta A

increases expression

Benzalkonium Compounds results in increased expression of INHBA mRNA

NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982

G

insulin induced gene 1

increases expression

Benzalkonium Compounds results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

ISL LIM homeobox 1

decreases expression

Benzalkonium Compounds results in decreased expression of ISL1 mRNA

NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584

G

iodotyrosine deiodinase

multiple interactions

Benzalkonium Compounds inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine]

NCBI chr 1:40,003,999...40,019,323
Ensembl chr 1:40,004,041...40,019,319

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Benzalkonium Compounds results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysine demethylase 7A

increases expression

Benzalkonium Compounds results in increased expression of KDM7A mRNA

NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998

G

lysine demethylase 8

decreases expression

Benzalkonium Compounds results in decreased expression of KDM8 mRNA

NCBI chr 1:180,013,969...180,028,829
Ensembl chr 1:180,020,656...180,028,841

G

KLF transcription factor 2

increases expression

Benzalkonium Compounds results in increased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

kallikrein related-peptidase 8

increases expression

Benzalkonium Compounds results in increased expression of KLK8 mRNA

NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646

G

keratin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRT2 mRNA

NCBI chr 7:132,940,879...132,948,031
Ensembl chr 7:132,940,862...132,947,963

G

keratin associated protein 14

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of KRTAP14 mRNA

NCBI chr11:28,126,660...28,127,502
Ensembl chr11:28,126,660...28,127,502

G

late cornified envelope 1M

decreases expression

Benzalkonium Compounds results in decreased expression of LCE1M mRNA

NCBI chr 2:178,637,495...178,638,697
Ensembl chr 2:178,637,495...178,638,697

G

lactate dehydrogenase A

decreases expression

Benzalkonium Compounds results in decreased expression of LDHA mRNA

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

low density lipoprotein receptor

increases expression

Benzalkonium Compounds results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

LIF, interleukin 6 family cytokine

increases expression

Benzalkonium Compounds results in increased expression of LIF protein

NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482

G

U6 spliceosomal RNA

decreases expression

Benzalkonium Compounds results in decreased expression of RNU6-643P

NCBI chr15:99,491,045...99,491,148
Ensembl chr15:99,491,045...99,491,148

G

small nucleolar RNA SNORA71

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA71D mRNA

NCBI chr 1:232,131,169...232,131,300
Ensembl chr 1:232,131,169...232,131,300

G

lysyl oxidase-like 1

decreases expression

Benzalkonium Compounds results in decreased expression of LOXL1 mRNA

NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:58,692,593...58,716,356

G

leukocyte specific transcript 1

increases expression

Benzalkonium Compounds results in increased expression of LST1 mRNA

NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997

G

lymphotoxin beta

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of LTB mRNA

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

mitogen activated protein kinase 14

increases phosphorylation

Benzalkonium Compounds results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mesoderm posterior bHLH transcription factor 2

decreases expression

Benzalkonium Compounds results in decreased expression of MESP2 mRNA

NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198

G

macrophage migration inhibitory factor

increases secretion

Benzalkonium Compounds results in increased secretion of MIF protein

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
Ensembl chr 4:12,790,902...12,799,504

G

matrix metallopeptidase 10

increases expression

Benzalkonium Compounds results in increased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 12

increases expression

Benzalkonium Compounds results in increased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 2

increases activity

Benzalkonium Compounds results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 25

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP25 mRNA

NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871

G

matrix metallopeptidase 9

multiple interactions
increases activity

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MMP9 mRNA
Benzalkonium Compounds results in increased activity of MMP9 protein

PMID:21058936 PMID:30171875

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

methylsterol monooxygenase 1

increases expression

Benzalkonium Compounds results in increased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

msh homeobox 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MSX2 mRNA

NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879

G

metallothionein 2A

decreases expression

Benzalkonium Compounds results in decreased expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

Benzalkonium Compounds results in decreased expression of MTHFD2 mRNA

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

myosin light chain kinase 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of MYLK3 mRNA

NCBI chr19:21,685,085...21,743,587
Ensembl chr19:21,691,929...21,742,954

G

Ndufa4, mitochondrial complex associated

decreases expression

Benzalkonium Compounds results in decreased expression of NDUFA4 mRNA

NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920

G

nuclear receptor subfamily 4, group A, member 2

increases expression

Benzalkonium Compounds results in increased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

neuregulin 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of NRG2 mRNA

NCBI chr18:27,616,542...27,798,505
Ensembl chr18:27,619,661...27,798,505

G

neurotrophic receptor tyrosine kinase 3

affects response to substance

NTRK3 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr 1:132,116,472...132,503,849
Ensembl chr 1:132,132,849...132,503,286

G

occludin

decreases expression

Benzalkonium Compounds results in decreased expression of OCLN protein

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

ornithine decarboxylase 1

decreases expression

Benzalkonium Compounds results in decreased expression of ODC1 mRNA

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

oxidized low density lipoprotein receptor 1

increases expression

Benzalkonium Compounds results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

orosomucoid 1

decreases expression

Benzalkonium Compounds results in decreased expression of ORM1 mRNA

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Benzalkonium Compounds analog results in increased cleavage of PARP1 protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Benzalkonium Compounds analog results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PDZ binding kinase

increases expression

Benzalkonium Compounds results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

proprotein convertase subtilisin/kexin type 9

decreases expression

Benzalkonium Compounds results in decreased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

programmed cell death 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PDCD1 mRNA

NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937

G

prefoldin subunit 6

affects response to substance

PFDN6 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,945,959...4,947,433

G

peptidoglycan recognition protein 3

increases expression

Benzalkonium Compounds results in increased expression of PGLYRP3 mRNA

NCBI chr 2:177,479,693...177,490,769
Ensembl chr 2:177,477,407...177,490,736
Ensembl chr 2:177,477,407...177,490,736

G

phosphoglycolate phosphatase

increases expression

Benzalkonium Compounds results in increased expression of PGP mRNA

NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858

G

phospholipase A2, group V

decreases expression

Benzalkonium Compounds results in decreased expression of PLA2G5 mRNA

NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658

G

phosphatidylinositol-specific phospholipase C, X domain containing 3

increases expression

Benzalkonium Compounds results in increased expression of PLCXD3 mRNA

NCBI chr 2:53,567,022...53,746,384
Ensembl chr 2:53,567,022...53,746,384

G

polo-like kinase 2

decreases expression

Benzalkonium Compounds results in decreased expression of PLK2 mRNA

NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947

G

patatin-like phospholipase domain containing 2

decreases expression

Benzalkonium Compounds results in decreased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

RNA polymerase I and III subunit D

decreases expression

Benzalkonium Compounds results in decreased expression of POLR1D mRNA

NCBI chr12:7,970,592...8,004,157
Ensembl chr12:7,970,595...8,005,624

G

peroxisome proliferator activated receptor alpha

decreases expression

Benzalkonium Compounds results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression

Benzalkonium Compounds results in increased expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

protein kinase AMP-activated non-catalytic subunit gamma 2

increases expression

Benzalkonium Compounds results in increased expression of PRKAG2 mRNA

NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,010,890...10,252,142

G

prokineticin receptor 2

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PROKR2 mRNA

NCBI chr 3:119,624,738...119,639,442
Ensembl chr 3:119,627,601...119,635,718

G

prostaglandin-endoperoxide synthase 2

increases expression

Benzalkonium Compounds results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

pentraxin 3

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323

G

ral guanine nucleotide dissociation stimulator like 2

affects response to substance

RGL2 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,948,495...4,956,774
Ensembl chr20:4,948,497...4,969,911

G

regenerating family member 1 alpha

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG1 mRNA

NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570

G

regenerating family member 3 gamma

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of REG3G mRNA

NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723

G

ribosomal protein S18

affects response to substance

RPS18 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,931,427...4,935,538
Ensembl chr20:4,931,768...4,938,315

G

RT1 class II, locus DOa

affects response to substance

HLA-DOA SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

affects response to substance

HLA-DOB SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

RT1 class II, locus Ha

affects response to substance

HLA-DPA1 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

RT1 class II, locus Hb, pseudogene 1

affects response to substance

HLA-DPB1 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618

G

ryanodine receptor 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

stearoyl-CoA desaturase

increases expression
decreases expression

Benzalkonium Compounds results in increased expression of SCD mRNA
Benzalkonium Compounds results in decreased expression of SCD1 mRNA

PMID:29155129 PMID:31199489

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

serpin family B member 13

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SERPINB13 mRNA

NCBI chr13:23,118,582...23,150,352
Ensembl chr13:23,118,584...23,150,760

G

serpin family E member 1

increases expression

Benzalkonium Compounds results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

sestrin 2

decreases expression

Benzalkonium Compounds results in decreased expression of SESN2 mRNA

NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260

G

stratifin

increases expression

Benzalkonium Compounds results in increased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

secreted frizzled-related protein 4

decreases expression

Benzalkonium Compounds results in decreased expression of SFRP4 mRNA

NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736

G

solute carrier family 16 member 1

increases expression

Benzalkonium Compounds results in increased expression of SLC16A1 mRNA

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

solute carrier family 7 member 11

increases expression

Benzalkonium Compounds results in increased expression of SLC7A11 mRNA

PMID:30806763 PMID:37149095

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

small nucleolar RNA, H/ACA box 38

decreases expression

Benzalkonium Compounds results in decreased expression of SNORA38

NCBI chr20:3,660,900...3,661,033
Ensembl chr20:3,660,900...3,661,033
Ensembl chr 9:3,660,900...3,661,033

G

SRY-box transcription factor 21

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SOX21 mRNA

NCBI chr15:95,292,429...95,296,024
Ensembl chr15:95,292,265...95,296,091

G

small proline-rich protein 1A

increases expression

Benzalkonium Compounds results in increased expression of SPRR1A mRNA

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

increases expression

Benzalkonium Compounds results in increased expression of SPRR1B mRNA

NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567

G

small proline rich protein 2A

increases expression

Benzalkonium Compounds results in increased expression of SPRR2H mRNA

NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236

G

small proline rich protein 2B

increases expression

Benzalkonium Compounds results in increased expression of SPRR2B mRNA

NCBI chr 2:177,852,824...177,853,096
Ensembl chr 2:177,852,824...177,853,096

G

small proline rich protein 2F

increases expression

Benzalkonium Compounds results in increased expression of SPRR2F mRNA

NCBI chr 2:177,989,974...177,990,204
Ensembl chr 2:177,989,974...177,990,204

G

squalene epoxidase

increases expression

Benzalkonium Compounds results in increased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sterol regulatory element binding transcription factor 2

increases expression

Benzalkonium Compounds results in increased expression of SREBF2 mRNA

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of SRMS mRNA

NCBI chr 3:168,318,511...168,324,915
Ensembl chr 3:168,318,512...168,324,915

G

ST14 transmembrane serine protease matriptase

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of ST14 mRNA

NCBI chr 8:29,540,805...29,581,704
Ensembl chr 8:29,540,811...29,581,517

G

TAP binding protein

affects response to substance

TAPBP SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,956,937...4,966,191
Ensembl chr20:4,956,937...4,966,181

G

transcription factor AP-2 beta

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TFAP2B mRNA

NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:21,786,258...21,814,520

G

transforming growth factor, beta 1

increases expression

Benzalkonium Compounds results in increased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transglutaminase 3

increases expression

Benzalkonium Compounds results in increased expression of TGM3 mRNA

NCBI chr 3:117,228,661...117,264,078
Ensembl chr 3:117,228,661...117,264,075

G

transglutaminase 7

decreases expression

Benzalkonium Compounds results in decreased expression of TGM7 mRNA

NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239

G

thrombospondin 1

increases expression

Benzalkonium Compounds results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

toll-like receptor 1

increases expression

Benzalkonium Compounds results in increased expression of TLR1 mRNA

NCBI chr14:43,384,127...43,396,765
Ensembl chr14:43,384,932...43,397,125

G

toll-like receptor 4

increases activity

Benzalkonium Compounds results in increased activity of TLR4 protein

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

transmembrane serine protease 11B

increases expression

Benzalkonium Compounds results in increased expression of TMPRSS11B mRNA

NCBI chr14:21,383,936...21,407,283
Ensembl chr14:21,383,862...21,408,817

G

tumor necrosis factor

decreases secretion
increases expression

Benzalkonium Compounds results in decreased secretion of TNF protein
Benzalkonium Compounds results in increased expression of TNF mRNA; Benzalkonium Compounds results in increased expression of TNF protein

PMID:29953848 PMID:30171875 PMID:30517752

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 6

increases expression

Benzalkonium Compounds results in increased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

TNF receptor superfamily member 13C

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFRSF13C mRNA

NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517

G

TNF receptor superfamily member 9

increases expression

Benzalkonium Compounds results in increased expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

TNF superfamily member 8

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TNFSF8 mRNA

NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421

G

tumor protein p53

decreases expression

Benzalkonium Compounds results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

triosephosphate isomerase 1

decreases expression

Benzalkonium Compounds results in decreased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

triggering receptor expressed on myeloid cells 2

increases expression

Benzalkonium Compounds results in increased expression of TREM2 mRNA

NCBI chr 9:12,647,605...12,654,190
Ensembl chr 9:12,647,259...12,654,170

G

tribbles pseudokinase 3

increases expression

Benzalkonium Compounds results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thymic stromal lymphopoietin

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of TSLP mRNA

NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548

G

UL16 binding protein 1

increases expression

Benzalkonium Compounds results in increased expression of ULBP1 mRNA

NCBI chr 1:1,694,255...1,716,160

G

uroplakin 3B

decreases expression

Benzalkonium Compounds results in decreased expression of UPK3B mRNA

NCBI chr12:20,630,231...20,637,634
Ensembl chr12:20,631,525...20,637,724

G

ubiquinol-cytochrome c reductase, complex III subunit VII

decreases expression

Benzalkonium Compounds results in decreased expression of UQCRQ mRNA

NCBI chr10:37,585,864...37,589,328
Ensembl chr10:37,586,888...37,589,169

G

vascular endothelial growth factor D

increases expression

Benzalkonium Compounds results in increased expression of VEGFD mRNA

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295

G

V-set domain containing T cell activation inhibitor 1

multiple interactions

[IL6 protein affects the susceptibility to Benzalkonium Compounds] which affects the expression of VTCN1 mRNA

NCBI chr 2:188,253,594...188,321,658
Ensembl chr 2:188,253,594...188,321,658

G

WD repeat domain 46

affects response to substance

WDR46 SNP affects the susceptibility to Benzalkonium Compounds

NCBI chr20:4,937,845...4,945,796
Ensembl chr20:4,937,847...4,946,535

G

X-box binding protein 1

decreases expression

Benzalkonium Compounds results in decreased expression of XBP1 mRNA alternative form

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

X-C motif chemokine ligand 1

decreases expression

Benzalkonium Compounds results in decreased expression of XCL1 mRNA

NCBI chr13:77,248,687...77,252,343
Ensembl chr13:77,248,717...77,252,329

butylscopolamine bromide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 2

multiple interactions

Butylscopolammonium Bromide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

chlormequat chloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 1700009N14 gene like

increases expression

Chlormequat results in increased expression of 1700009N14RIKL protein

NCBI chr 5:54,456,005...54,457,381
Ensembl chr 5:54,455,893...54,457,677

G

ATP binding cassette subfamily D member 1

increases expression

Chlormequat results in increased expression of ABCD1 protein

NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115

G

adenosine deaminase, RNA-specific, B1

decreases expression

Chlormequat results in decreased expression of ADARB1 protein

NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852

G

angiotensin II receptor-associated protein

increases expression

Chlormequat results in increased expression of AGTRAP protein

NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036

G

aryl hydrocarbon receptor

multiple interactions

Chlormequat promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

ALG12, alpha-1,6-mannosyltransferase

decreases expression

Chlormequat results in decreased expression of ALG12 protein

NCBI chr 7:119,895,112...119,909,488
Ensembl chr 7:119,895,120...119,909,458

G

ALG14, UDP-N-acetylglucosaminyltransferase subunit

decreases expression

Chlormequat results in decreased expression of ALG14 protein

NCBI chr 2:209,368,285...209,445,425
Ensembl chr 2:209,368,312...209,445,431

G

apolipoprotein L9a

increases expression

Chlormequat results in increased expression of APOL9A protein

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

Rho GTPase activating protein 20

increases expression

Chlormequat results in increased expression of ARHGAP20 protein

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739

G

atlastin GTPase 1

increases expression

Chlormequat results in increased expression of ATL1 protein

NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204

G

ATPase phospholipid transporting 10B

increases expression

Chlormequat results in increased expression of ATP10B protein

NCBI chr10:27,495,207...27,751,313
Ensembl chr10:27,408,747...27,749,637

G

B9 domain containing 2

increases expression

Chlormequat results in increased expression of B9D2 protein

NCBI chr 1:81,189,395...81,195,383
Ensembl chr 1:81,189,405...81,195,356

G

Bet1 golgi vesicular membrane trafficking protein-like

increases expression

Chlormequat results in increased expression of BET1L protein

NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040

G

bone gamma-carboxyglutamate protein

decreases expression

Chlormequat results in decreased expression of BGLAP protein

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

complement C1q C chain

increases expression

Chlormequat results in increased expression of C1QC protein

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

caspase activity and apoptosis inhibitor 1

decreases expression

Chlormequat results in decreased expression of CAAP1 protein

NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314

G

chromobox 1

increases expression

Chlormequat results in increased expression of CBX1 protein

NCBI chr10:81,770,307...81,789,981
Ensembl chr10:81,770,342...81,791,096

G

coiled-coil domain containing 32

increases expression

Chlormequat results in increased expression of CCDC32 protein

NCBI chr 3:105,998,429...106,010,985
Ensembl chr 3:105,998,430...106,010,975

G

cyclin Y-like 1

increases expression

Chlormequat results in increased expression of CCNYL1 protein

NCBI chr 9:66,071,721...66,121,742
Ensembl chr 9:66,071,543...66,107,999

G

copper chaperone for superoxide dismutase

increases expression

Chlormequat results in increased expression of CCS protein

NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915

G

CD151 molecule (Raph blood group)

decreases expression

Chlormequat results in decreased expression of CD151 protein

NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753

G

CD55 molecule (Cromer blood group)

increases expression

Chlormequat results in increased expression of CD55 protein

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

cilia and flagella associated protein 298

increases expression

Chlormequat results in increased expression of CFAP298 protein

NCBI chr11:30,181,916...30,191,302
Ensembl chr11:30,181,905...30,191,346

G

charged multivesicular body protein 7

increases expression

Chlormequat results in increased expression of CHMP7 protein

NCBI chr15:44,790,983...44,806,216
Ensembl chr15:44,790,996...44,806,216

G

coordinator of PRMT5 and differentiation stimulator

increases expression

Chlormequat results in increased expression of COPRS protein

NCBI chr16:75,721,264...75,726,375
Ensembl chr16:75,720,061...75,726,375

G

coenzyme Q4

increases expression

Chlormequat results in increased expression of COQ4 protein

NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799

G

cAMP responsive element binding protein 1

increases phosphorylation

Chlormequat results in increased phosphorylation of CREB1 protein

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

casein kinase 1, alpha 1

increases expression

Chlormequat results in increased expression of CSNK1A1 protein

NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271

G

cathepsin S

decreases expression

Chlormequat results in decreased expression of CTSS protein

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Chlormequat results in decreased expression of CYP11A1 protein

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450 family 7 subfamily A member 1

increases expression

Chlormequat results in increased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

death-associated protein

decreases expression

Chlormequat results in decreased expression of DAP protein

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

DDB1 and CUL4 associated factor 13

increases expression

Chlormequat results in increased expression of DCAF13 protein

NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142

G

dynactin subunit 6

increases expression

Chlormequat results in increased expression of DCTN6 protein

NCBI chr16:58,077,595...58,096,604
Ensembl chr16:58,077,585...58,096,968

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

delta(4)-desaturase, sphingolipid 1

increases expression

Chlormequat results in increased expression of DEGS1 protein

NCBI chr13:93,946,154...93,953,677
Ensembl chr13:93,946,157...93,953,664

G

DnaJ heat shock protein family (Hsp40) member C14

increases expression

Chlormequat results in increased expression of DNAJC14 protein

NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645

G

dynamin binding protein

increases expression

Chlormequat results in increased expression of DNMBP protein

NCBI chr 1:242,736,189...242,829,431
Ensembl chr 1:242,736,189...242,802,604

G

dynein light chain Tctex-type 3

increases expression

Chlormequat results in increased expression of DYNLT3 protein

NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139

G

glutamyl-tRNA synthetase 2, mitochondrial

increases expression

Chlormequat results in increased expression of EARS2 protein

NCBI chr 1:176,597,986...176,625,848
Ensembl chr 1:176,597,986...176,625,836

G

eukaryotic translation elongation factor 1 alpha 2

decreases expression

Chlormequat results in decreased expression of EEF1A2 protein

NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071

G

ELOVL fatty acid elongase 1

increases expression

Chlormequat results in increased expression of ELOVL1 protein

NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958

G

ELOVL fatty acid elongase 5

increases expression

Chlormequat results in increased expression of ELOVL5 protein

NCBI chr 8:78,790,846...78,857,307
Ensembl chr 8:78,790,846...78,857,284

G

enolase 3

decreases expression

Chlormequat results in decreased expression of ENO3 protein

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

EvC ciliary complex subunit 1

increases expression

Chlormequat results in increased expression of EVC protein

NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099

G

fatty acid binding protein 4

decreases expression

Chlormequat results in decreased expression of FABP4 protein

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

FA complementation group D2

decreases expression

Chlormequat results in decreased expression of FANCD2 protein

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

fibulin 1

increases expression

Chlormequat results in increased expression of FBLN1 protein

NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

Chlormequat results in decreased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box K2

decreases expression

Chlormequat results in decreased expression of FOXK2 protein

NCBI chr10:106,542,643...106,592,569
Ensembl chr10:106,542,566...106,592,563

G

GABA type A receptor-associated protein

increases expression

Chlormequat results in increased expression of GABARAP protein

NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765

G

growth hormone 1

increases expression

Chlormequat results in increased expression of GH1 protein

PMID:31704167 PMID:32622971 PMID:38552810

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

growth hormone receptor

decreases expression

Chlormequat results in decreased expression of GHR mRNA

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

growth hormone releasing hormone

increases expression

Chlormequat results in increased expression of GHRH protein

PMID:32622971 PMID:38552810

NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889

G

G protein subunit alpha i1

increases expression

Chlormequat results in increased expression of GNAI1 protein

NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417

G

G protein subunit gamma 5

decreases expression

Chlormequat results in decreased expression of GNG5 protein

NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
Ensembl chr11:77,292,043...77,292,513

G

gonadotropin releasing hormone 1

increases expression

Chlormequat results in increased expression of GNRH1 protein

NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581

G

glutathione S-transferase alpha 2

increases expression

Chlormequat results in increased expression of GSTA2 protein

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

general transcription factor IIH subunit 5

increases expression

Chlormequat results in increased expression of GTF2H5 protein

NCBI chr 1:46,656,804...46,663,512
Ensembl chr 1:46,656,859...46,664,939

G

H1.0 linker histone

increases expression

Chlormequat results in increased expression of H1-0 protein

NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694

G

H1.5 linker histone, cluster member

increases expression

Chlormequat results in increased expression of H1-5 protein

NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160

G

heme binding protein 2

increases expression

Chlormequat results in increased expression of HEBP2 protein

NCBI chr 1:13,194,982...13,201,777
Ensembl chr 1:13,194,982...13,201,777

G

HERPUD family member 2

increases expression

Chlormequat results in increased expression of HERPUD2 protein

NCBI chr 8:23,573,374...23,618,380
Ensembl chr 8:23,573,379...23,617,874

G

heterogeneous nuclear ribonucleoprotein C

increases expression

Chlormequat results in increased expression of HNRNPC protein

NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases expression

Chlormequat results in decreased expression of HSD3B1 protein

NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

insulin-like growth factor 1

affects expression
increases expression

Chlormequat affects the expression of IGF1 protein
Chlormequat results in increased expression of IGF1 protein

PMID:28214531 PMID:31704167

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

internexin neuronal intermediate filament protein, alpha

decreases expression

Chlormequat results in decreased expression of INA protein

NCBI chr 1:245,896,775...245,908,330
Ensembl chr 1:245,896,775...245,908,330

G

isochorismatase domain containing 2b

increases expression

Chlormequat results in increased expression of ISOC2 protein

NCBI chr 1:68,972,960...68,993,760
Ensembl chr 1:68,972,960...68,993,757

G

integrin subunit beta 1 binding protein 1

increases expression

Chlormequat results in increased expression of ITGB1BP1 protein

NCBI chr 6:40,820,693...40,836,074
Ensembl chr 6:40,821,339...40,836,037

G

kazrin, periplakin interacting protein

increases expression

Chlormequat results in increased expression of KAZN protein

NCBI chr 5:154,392,793...155,381,567
Ensembl chr 5:154,392,793...154,779,074

G

kelch-like family member 26

decreases expression

Chlormequat results in decreased expression of KLHL26 protein

NCBI chr16:18,952,123...18,977,328
Ensembl chr16:18,952,234...18,977,328

G

kelch-like family member 7

decreases expression

Chlormequat results in decreased expression of KLHL7 protein

NCBI chr 4:11,006,366...11,055,399
Ensembl chr 4:11,006,375...11,055,541

G

LIM domain binding 1

increases expression

Chlormequat results in increased expression of LDB1 protein

NCBI chr 1:244,864,168...244,890,007
Ensembl chr 1:244,877,173...244,890,013

G

luteinizing hormone subunit beta

increases expression

Chlormequat results in increased expression of LHB protein

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

leucine rich repeat containing 7

increases expression

Chlormequat results in increased expression of LRRC7 protein

NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547

G

macroH2A.1 histone

increases expression

Chlormequat results in increased expression of MACROH2A1 protein

NCBI chr17:8,479,331...8,542,071
Ensembl chr17:8,479,372...8,542,072

G

macroH2A.2 histone

increases expression

Chlormequat results in increased expression of MACROH2A2 protein

NCBI chr20:29,678,194...29,727,867
Ensembl chr20:29,678,222...29,727,891

G

microtubule-associated protein 4

decreases expression

Chlormequat results in decreased expression of MAP4 protein

NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B

increases expression

Chlormequat results in increased expression of MGAT4B protein

NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229

G

motile sperm domain containing 3

decreases expression

Chlormequat results in decreased expression of MOSPD3 protein

NCBI chr12:19,095,203...19,100,303
Ensembl chr12:19,095,242...19,099,477

G

Mov10 RNA helicase

increases expression

Chlormequat results in increased expression of MOV10 protein

NCBI chr 2:192,292,041...192,315,142
Ensembl chr 2:192,293,470...192,315,083

G

MAGUK p55 scaffold protein 2

decreases expression

Chlormequat results in decreased expression of MPP2 protein

NCBI chr10:87,011,434...87,043,883
Ensembl chr10:87,011,434...87,043,896

G

MPV17 mitochondrial inner membrane protein like 2

increases expression

Chlormequat results in increased expression of MPV17L2 protein

NCBI chr16:18,680,106...18,684,212
Ensembl chr16:18,681,826...18,684,212

G

mitochondrial ribosomal protein L51

increases expression

Chlormequat results in increased expression of MRPL51 protein

NCBI chr 4:157,991,756...157,994,715
Ensembl chr 4:157,992,408...157,995,414

G

mitochondrial ribosomal protein L54

increases expression

Chlormequat results in increased expression of MRPL54 protein

NCBI chr 7:8,452,801...8,455,321
Ensembl chr 7:8,452,716...8,455,321

G

mitochondrial ribosomal protein S14

increases expression

Chlormequat results in increased expression of MRPS14 protein

NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915

G

mitochondrial translation release factor in rescue

increases expression

Chlormequat results in increased expression of MTRFR protein

NCBI chr12:32,261,569...32,275,258
Ensembl chr12:32,258,435...32,275,258

G

nucleolin

increases expression

Chlormequat results in increased expression of NCL protein

NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136

G

NHP2 ribonucleoprotein

increases expression

Chlormequat results in increased expression of NHP2 protein

NCBI chr10:35,877,057...35,880,399
Ensembl chr10:35,877,054...35,882,545

G

NIPA magnesium transporter 1

decreases expression

Chlormequat results in decreased expression of NIPA1 protein

NCBI chr 1:106,834,000...106,875,148
Ensembl chr 1:106,834,000...106,874,790

G

natriuretic peptide receptor 3

decreases expression

Chlormequat results in decreased expression of NPR3 protein

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

nuclear receptor subfamily 3, group C, member 2

increases expression

Chlormequat results in increased expression of NR3C2 protein

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

ORAI calcium release-activated calcium modulator 1

increases expression

Chlormequat results in increased expression of ORAI1 protein

NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405

G

poly(A) binding protein, cytoplasmic 1

increases expression

Chlormequat results in increased expression of PABPC1 protein

NCBI chr 7:67,777,438...67,789,731
Ensembl chr 7:67,777,381...67,789,744

G

poly(A) binding protein, cytoplasmic 4

increases expression

Chlormequat results in increased expression of PABPC4 protein

NCBI chr 5:135,563,142...135,578,985
Ensembl chr 5:135,563,562...135,578,979

G

propionyl-CoA carboxylase subunit beta

increases expression

Chlormequat results in increased expression of PCCB protein

NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234

G

peroxisomal biogenesis factor 26

increases expression

Chlormequat results in increased expression of PEX26 protein

NCBI chr 4:154,414,332...154,426,954
Ensembl chr 4:154,414,849...154,426,952

G

pyroglutamyl-peptidase I

increases expression

Chlormequat results in increased expression of PGPEP1 protein

NCBI chr16:18,770,563...18,782,968
Ensembl chr16:18,771,021...18,783,478

G

pleckstrin homology-like domain, family B, member 1

increases expression

Chlormequat results in increased expression of PHLDB1 protein

NCBI chr 8:45,003,543...45,051,541
Ensembl chr 8:45,003,538...45,051,522

G

protein inhibitor of activated STAT, 3

decreases expression

Chlormequat results in decreased expression of PIAS3 protein

NCBI chr 2:184,232,546...184,241,455
Ensembl chr 2:184,232,571...184,241,480

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta

increases expression

Chlormequat results in increased expression of PIK3CD protein

NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930

G

phosphatidylinositol transfer protein, membrane-associated 2

increases expression

Chlormequat results in increased expression of PITPNM2 protein

NCBI chr12:32,347,455...32,479,103
Ensembl chr12:32,380,805...32,479,102

G

DNA polymerase epsilon 4, accessory subunit

increases expression

Chlormequat results in increased expression of POLE4 protein

NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097

G

POU class 1 homeobox 1

increases expression

Chlormequat results in increased expression of POU1F1 protein

NCBI chr11:3,316,818...3,334,804
Ensembl chr11:3,317,058...3,334,801

G

periphilin 1

increases expression

Chlormequat results in increased expression of PPHLN1 protein

NCBI chr 7:124,538,594...124,629,985
Ensembl chr 7:124,538,627...124,629,985

G

protein kinase cAMP-activated catalytic subunit alpha

affects expression

Chlormequat affects the expression of PRKACA protein

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

protein kinase cAMP-dependent type I regulatory subunit beta

increases expression

Chlormequat results in increased expression of PRKAR1B protein

NCBI chr12:15,492,233...15,624,942
Ensembl chr12:15,511,801...15,624,942

G

proteasome 20S subunit beta 7

increases expression

Chlormequat results in increased expression of PSMB7 protein

NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937

G

RAB6A, member RAS oncogene family

increases expression

Chlormequat results in increased expression of RAB6A protein

NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715

G

RAD17 checkpoint clamp loader component

increases expression

Chlormequat results in increased expression of RAD17 protein

NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:31,764,261...31,794,072

G

ras homolog family member Q

increases expression

Chlormequat results in increased expression of RHOQ protein

NCBI chr 6:7,613,632...7,652,047
Ensembl chr 1:106,622,141...106,623,699

G

ring finger protein 113A1

decreases expression

Chlormequat results in decreased expression of RNF113A1 protein

NCBI chr X:116,427,941...116,429,164
Ensembl chr X:116,427,684...116,433,762

G

ring finger protein 185

increases expression
multiple interactions

Chlormequat results in increased expression of RNF185 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of RNF185 protein]

NCBI chr14:78,292,517...78,329,832
Ensembl chr14:78,292,516...78,329,864

G

ring finger and SPRY domain containing 1

increases expression

Chlormequat results in increased expression of RSPRY1 protein

NCBI chr19:10,352,449...10,403,015
Ensembl chr19:10,353,821...10,401,102

G

reticulon 1

decreases expression

Chlormequat results in decreased expression of RTN1 protein

NCBI chr 6:90,763,212...90,983,436
Ensembl chr 6:90,763,216...90,983,436

G

S100 calcium binding protein A1

increases expression

Chlormequat results in increased expression of S100A1 protein

NCBI chr 2:175,993,922...175,998,765
Ensembl chr 2:175,993,922...175,999,544

G

sterile alpha motif domain containing 8

increases expression

Chlormequat results in increased expression of SAMD8 protein

NCBI chr15:2,512,104...2,562,368
Ensembl chr15:2,512,105...2,515,379
Ensembl chr15:2,512,105...2,515,379

G

secretion associated, Ras related GTPase 1A

increases expression

Chlormequat results in increased expression of SAR1A protein

NCBI chr20:29,623,529...29,635,935
Ensembl chr20:29,623,553...29,635,935

G

shroom family member 1

decreases expression

Chlormequat results in decreased expression of SHROOM1 protein

NCBI chr10:37,621,149...37,631,895
Ensembl chr10:37,621,723...37,631,256

G

Ski proto-oncogene

increases expression

Chlormequat results in increased expression of SKI protein

NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733

G

solute carrier family 48 member 1

decreases expression

Chlormequat results in decreased expression of SLC48A1 protein

NCBI chr 7:128,915,136...128,923,929
Ensembl chr 7:128,915,195...128,923,024

G

slit guidance ligand 3

increases expression

Chlormequat results in increased expression of SLIT3 protein

NCBI chr10:19,571,798...20,156,634
Ensembl chr10:19,571,684...20,156,634

G

SLU7 homolog, splicing factor

increases expression

Chlormequat results in increased expression of SLU7 protein

NCBI chr10:27,908,325...27,923,784
Ensembl chr10:27,908,396...27,923,349

G

small integral membrane protein 26

decreases expression

Chlormequat results in decreased expression of SMIM26 protein

NCBI chr 3:131,990,147...131,991,779
Ensembl chr 3:131,990,291...131,992,132

G

SPNS lysolipid transporter 1, lysophospholipid

increases expression

Chlormequat results in increased expression of SPNS1 protein

NCBI chr 1:180,942,088...180,949,415
Ensembl chr 1:180,942,088...180,949,370

G

signal peptide peptidase-like 2B

increases expression

Chlormequat results in increased expression of SPPL2B protein

NCBI chr 7:8,843,918...8,856,642
Ensembl chr 7:8,843,918...8,856,608

G

somatostatin

affects expression

Chlormequat affects the expression of SST protein

NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 1

increases expression

Chlormequat results in increased expression of ST3GAL1 protein

NCBI chr 7:98,845,270...98,913,409
Ensembl chr 7:98,845,270...98,913,236

G

suppression of tumorigenicity 7-like

decreases expression

Chlormequat results in decreased expression of ST7L protein

NCBI chr 2:192,364,594...192,434,414
Ensembl chr 2:192,364,594...192,487,190

G

steroidogenic acute regulatory protein

decreases expression

Chlormequat results in decreased expression of STAR protein

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

serine/threonine kinase 26

increases expression

Chlormequat results in increased expression of STK26 protein

NCBI chr X:130,325,064...130,375,674
Ensembl chr X:130,310,885...130,374,291

G

sushi domain containing 2

increases expression

Chlormequat results in increased expression of SUSD2 protein

NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903

G

TATA-box binding protein associated factor 7

increases expression

Chlormequat results in increased expression of TAF7 protein

NCBI chr18:29,459,937...29,462,086
Ensembl chr18:29,452,943...29,462,134

G

TRPM8 channel-associated factor 1

increases expression

Chlormequat results in increased expression of TCAF1 protein

NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309

G

transcription elongation factor A N-terminal and central domain containing

decreases expression

Chlormequat results in decreased expression of TCEANC protein

NCBI chr X:27,952,539...27,961,038
Ensembl chr X:27,952,457...27,960,940

G

terminal nucleotidyltransferase 2

increases expression

Chlormequat results in increased expression of TENT2 protein

NCBI chr 2:24,380,135...24,432,099
Ensembl chr 2:24,380,225...24,432,099

G

thioesterase superfamily member 4

decreases expression

Chlormequat results in decreased expression of THEM4 protein

NCBI chr 2:181,953,550...181,974,708
Ensembl chr 2:181,953,550...181,974,708

G

THO complex subunit 6

increases expression

Chlormequat results in increased expression of THOC6 protein

NCBI chr10:12,700,051...12,705,411
Ensembl chr10:12,700,051...12,706,925

G

TIR domain containing adaptor protein

increases expression

Chlormequat results in increased expression of TIRAP protein

NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432

G

transketolase

increases expression

Chlormequat results in increased expression of TKT protein

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

transmembrane protein 106C

increases expression

Chlormequat results in increased expression of TMEM106C protein

NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130

G

transmembrane protein 184C

decreases expression

Chlormequat results in decreased expression of TMEM184C protein

NCBI chr19:30,345,183...30,361,275
Ensembl chr19:30,345,290...30,361,269

G

transmembrane protein 208

increases expression

Chlormequat results in increased expression of TMEM208 protein

NCBI chr19:33,203,587...33,206,287
Ensembl chr19:33,203,587...33,212,183

G

transmembrane protein 222

increases expression

Chlormequat results in increased expression of TMEM222 protein

NCBI chr 5:145,465,847...145,477,932
Ensembl chr 5:145,465,847...145,484,491

G

TNF superfamily member 11

affects expression

Chlormequat affects the expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53 inducible protein 11

increases expression

Chlormequat results in increased expression of TP53I11 protein

NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:79,144,895...79,160,050

G

transformer 2 alpha

increases expression

Chlormequat results in increased expression of TRA2A protein

NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712

G

translocation associated membrane protein 2

decreases expression

Chlormequat results in decreased expression of TRAM2 protein

NCBI chr 9:23,419,204...23,498,745
Ensembl chr 9:23,424,232...23,498,689

G

tetratricopeptide repeat domain 12

increases expression

Chlormequat results in increased expression of TTC12 protein

NCBI chr 8:49,799,916...49,847,940
Ensembl chr 8:49,799,920...49,847,087

G

ubiquitin-conjugating enzyme E2D 1

increases expression
multiple interactions

Chlormequat results in increased expression of UBE2D1 protein
4-phenylbutyric acid inhibits the reaction [Chlormequat results in increased expression of UBE2D1 protein]

NCBI chr20:17,309,315...17,343,770
Ensembl chr20:17,309,315...17,342,295

G

uncoupling protein 2

decreases expression

Chlormequat results in decreased expression of UCP2 protein

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

WD repeat domain 74

increases expression

Chlormequat results in increased expression of WDR74 protein

NCBI chr 1:205,631,769...205,636,558
Ensembl chr 1:205,631,824...205,636,563

G

WD repeat and SOCS box-containing 2

decreases expression

Chlormequat results in decreased expression of WSB2 protein

NCBI chr12:39,217,645...39,238,634
Ensembl chr12:39,217,648...39,238,640

G

zinc finger E-box binding homeobox 1

increases expression

Chlormequat results in increased expression of ZEB1 protein

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

cocaine hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

basic helix-loop-helix ARNT like 1

decreases expression

cocaine hydrochloride decreases expression of Bmal1 mRNA in caudate-putamen

RGD

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

clock circadian regulator

increases expression

cocaine hydrochloride increases expression of Clock mRNA in caudate-putamen

RGD

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

cryptochrome circadian regulator 1

decreases expression
increases expression

cocaine hydrochloride decreases expression of Cry1 mRNA in caudate-putamen
cocaine hydrochloride increases expression of Cry1 mRNA in hippocampal formation

RGD

PMID:15994025 PMID:15994025

RGD:405866347, RGD:405866347

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

cryptochrome circadian regulator 2

decreases expression

cocaine hydrochloride decreases expression of Cry2 mRNA in caudate-putamen

RGD

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

neuronal PAS domain protein 2

decreases expression

cocaine hydrochloride decreases expression of hippocampal formation and caudate-putamen

RGD

NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320

G

period circadian regulator 1

increases expression

cocaine hydrochloride increases expression of Per1 mRNA in hippocampal formation and caudate-putamen

RGD

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

increases expression
decreases expression

ocaine hydrochloride increases expression of Per2 mRNA in hippocampal formation
cocaine hydrochloride decreases expression of Per2 mRNA in caudate-putamen

RGD

PMID:15994025 PMID:15994025

RGD:405866348, RGD:405866348

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

period circadian regulator 3

increases expression

cocaine hydrochloride increases expression of Per3 mRNA in hippocampal formation and caudate-putamen

RGD

NCBI chr 5:161,460,228...161,495,404
Ensembl chr 5:161,459,533...161,495,607

colesevelam hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-reactive protein

decreases expression

Colesevelam Hydrochloride results in decreased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
increases expression

Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA]
Colesevelam Hydrochloride results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

low density lipoprotein receptor

increases expression

Colesevelam Hydrochloride results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

colforsin daropate hydrochloride

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions

Colforsin promotes the reaction [Diethylhexyl Phthalate results in decreased expression of ABCA1 mRNA]

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions
decreases expression

Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA]

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

increases expression

Colforsin results in increased expression of ABCC2 mRNA; Colforsin results in increased expression of ABCC2 protein

PMID:19580841 PMID:26049102

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 4

decreases expression
multiple interactions

Colforsin results in decreased expression of ABCC4 mRNA
Valproic Acid inhibits the reaction [Colforsin results in decreased expression of ABCC4 mRNA]

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

increases expression
multiple interactions

Colforsin results in increased expression of ABCG2 mRNA
Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]

PMID:19580841 PMID:30610963

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetyl-CoA carboxylase alpha

increases phosphorylation

Colforsin results in increased phosphorylation of ACACA protein

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acetylcholinesterase

increases activity
increases expression

Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form
Colforsin results in increased expression of ACHE mRNA

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA synthetase long-chain family member 3

increases expression

Colforsin results in increased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

Colforsin results in decreased expression of ACTA2 protein
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]

PMID:21603974 PMID:27590029

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

ADAM metallopeptidase domain 12

decreases expression

Colforsin results in decreased expression of ADAM12 mRNA

PMID:15313392 PMID:15967414

NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

decreases expression

Colforsin results in decreased expression of ADAMTS1 mRNA

PMID:15313392 PMID:15967414

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

adenylate cyclase 5

multiple interactions

ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole]

NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974

G

adenylate cyclase 6

affects response to substance

ADCY6 protein affects the susceptibility to Colforsin

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

adenylate cyclase 9

multiple interactions
increases activity

[Colforsin co-treated with Miconazole] results in increased activity of ADCY9 protein
Colforsin results in increased activity of ADCY9 protein

NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066

G

adrenomedullin

multiple interactions
increases expression

cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ADM mRNA]

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adrenoceptor alpha 1A

multiple interactions

[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium]

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 2C

multiple interactions
affects localization
increases expression

AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

adrenoceptor beta 1

affects response to substance
multiple interactions

ADRB1 protein polymorphism affects the susceptibility to Colforsin
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]

PMID:14502278 PMID:19419905

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
increases expression
increases phosphorylation

[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]
Colforsin results in increased expression of ADRB2 mRNA
Colforsin results in increased phosphorylation of ADRB2 protein

PMID:14722251 PMID:19419905 PMID:24705868

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

decreases expression

Colforsin results in decreased expression of ADRB3 mRNA

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

aryl hydrocarbon receptor

multiple interactions
affects localization

[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein]
AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA]

PMID:15972329 PMID:17329248 PMID:17823304 PMID:23291558

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

A-kinase anchoring protein 13

multiple interactions

AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

aldo-keto reductase family 1, member C3

decreases expression

Colforsin results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions

Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

multiple interactions

Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

albumin

multiple interactions

Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, intestinal

multiple interactions

Colforsin inhibits the reaction [Methotrexate results in increased activity of ALPI protein]

NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877

G

alkaline phosphatase, placental

increases expression
multiple interactions

Colforsin results in increased expression of ALPP mRNA
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA; Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Desipramine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

amine oxidase, copper containing 1

increases activity

Colforsin results in increased activity of AOC1 protein

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

amyloid beta precursor protein binding protein 2

decreases expression

Colforsin results in decreased expression of APPBP2 mRNA

NCBI chr10:70,057,774...70,099,877
Ensembl chr10:70,057,774...70,099,835

G

androgen receptor

multiple interactions
increases expression

AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein]
Colforsin results in increased expression of AR protein

PMID:16751804 PMID:17219378

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

increases expression
multiple interactions

Colforsin results in increased expression of AREG mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein]

PMID:15284208 PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

arrestin, beta 1

multiple interactions

Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

ataxin 3

decreases expression

Colforsin results in decreased expression of ATXN3 mRNA

NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902

G

BCL2, apoptosis regulator

multiple interactions

[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of BCL2 mRNA; S-(1,2-dichlorovinyl)cysteine inhibits the reaction [Colforsin results in increased expression of BCL2 mRNA]

PMID:36336211 PMID:37544576

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions
increases expression

1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein]
Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of BDNF protein]
Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein

PMID:19189864 PMID:35917217

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

basic helix-loop-helix ARNT like 1

increases expression

Colforsin results in increased expression of BMAL1 mRNA

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

bone morphogenetic protein 6

multiple interactions

BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

complement C4A

multiple interactions

[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of C4A mRNA

NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080

G

calcium voltage-gated channel subunit alpha1 G

multiple interactions

Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]

NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752

G

calcium voltage-gated channel subunit alpha1 H

multiple interactions

Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calcitonin receptor like receptor

multiple interactions

Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]

NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910

G

calcium/calmodulin-dependent protein kinase kinase 2

increases expression

Colforsin results in increased expression of CAMKK2 mRNA

NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279

G

calcium/calmodulin dependent serine protein kinase

multiple interactions
increases phosphorylation

Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein]

NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694

G

caspase 1

increases activity

Colforsin results in increased activity of CASP1 mRNA; Colforsin results in increased activity of CASP1 protein

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases activity
multiple interactions

Colforsin results in increased activity of CASP3 protein
Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein]
KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein]
Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein]

PMID:16396944 PMID:20131233 PMID:21745194 PMID:31278978

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 5

multiple interactions

Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

CD55 molecule (Cromer blood group)

multiple interactions
increases expression

3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Colforsin results in increased expression of CD55 mRNA]

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

cell division cycle 6

increases expression

Colforsin results in increased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cadherin 1

affects activity
increases expression

Colforsin affects the activity of CDH1 protein
Colforsin results in increased expression of CDH1 protein

PMID:10413674 PMID:30983542

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

CMT1A duplicated region transcript 4

multiple interactions

[Colforsin co-treated with Diethylhexyl Phthalate] affects the expression of CDRT4 mRNA

NCBI chr10:47,625,470...47,657,493
Ensembl chr10:47,625,470...47,657,493

G

CCAAT/enhancer binding protein alpha

multiple interactions
increases expression

Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA]
Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein]
Colforsin results in increased expression of CEBPA protein

PMID:17407152 PMID:21832167

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

increases expression
multiple interactions

Colforsin results in increased expression of CEBPB mRNA
[Atrazine co-treated with Colforsin] results in increased expression of CEBPB protein

PMID:14684744 PMID:25253736

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CF transmembrane conductance regulator

affects localization
increases activity
multiple interactions

Colforsin affects the localization of CFTR protein
Colforsin results in increased activity of CFTR protein
[Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein]
[1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin promotes the reaction [Nimodipine results in increased activity of CFTR protein]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]
Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form

PMID:12519745 PMID:12914781 PMID:14502435 PMID:14967738 PMID:15163550 More...

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

glycoprotein hormones, alpha polypeptide

increases secretion
increases expression
multiple interactions

Colforsin results in increased secretion of CGA protein
Colforsin results in increased expression of CGA protein
Colforsin results in increased expression of CGA mRNA
Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; perfluorobutanesulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]; perfluorooctane sulfonic acid inhibits the reaction [Colforsin results in increased expression of CGA protein]
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]

PMID:8404651 PMID:16503475 PMID:20378682 PMID:33144174

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cell death-inducing DFFA-like effector c

increases expression

Colforsin results in increased expression of CIDEC protein

NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173

G

cannabinoid receptor 1

multiple interactions
affects response to substance
increases activity

(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]
CNR1 protein affects the susceptibility to Colforsin

PMID:27429655 PMID:27527584 PMID:28861508 PMID:31154070

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions
increases activity
affects response to substance

(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]
CNR2 protein affects the susceptibility to Colforsin

PMID:17558435 PMID:27429655 PMID:27527584 PMID:28861508 PMID:30504240 More...

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cAMP responsive element binding protein 1

increases activity
increases expression
increases phosphorylation
multiple interactions

Colforsin results in increased activity of CREB1 protein
Colforsin results in increased expression of CREB1 mRNA; Colforsin results in increased expression of CREB1 protein modified form
Colforsin results in increased phosphorylation of CREB1 protein
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]
AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein; alisol B inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased phosphorylation of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]

PMID:10908723 PMID:11113530 PMID:15522277 PMID:17141199 PMID:17322281 More...

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

multiple interactions

Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cAMP responsive element modulator

increases expression

Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein

PMID:8810303 PMID:12791704

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

corticotropin releasing hormone

multiple interactions
increases secretion

CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone]
Colforsin results in increased secretion of CRH protein
[perfluorooctane sulfonic acid co-treated with Colforsin] results in increased expression of CRH mRNA

PMID:2153673 PMID:33144174

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cardiolipin synthase 1

increases expression

Colforsin results in increased expression of CRLS1 mRNA

NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655

G

crystallin, alpha B

multiple interactions

Colforsin inhibits the reaction [arsenite results in increased expression of CRYAB protein]

NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157

G

cytochrome P450, family 11, subfamily a, polypeptide 1

affects expression
multiple interactions
increases expression

Colforsin affects the expression of CYP11A1 mRNA
[Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA
Colforsin results in increased expression of CYP11A1 mRNA
[Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA]
[Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein]

PMID:14691014 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 More...

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases activity
increases expression
multiple interactions

Colforsin results in increased activity of CYP11B1 protein
Colforsin results in increased expression of CYP11B1 mRNA
[1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B1 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B1 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B1 mRNA]

PMID:12525251 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 More...

NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases expression
multiple interactions

Colforsin results in increased expression of CYP11B2 mRNA
[1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA]

PMID:16935330 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 More...

NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression
multiple interactions

Colforsin results in increased expression of CYP17A1 mRNA
[Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]

PMID:15625562 PMID:15886251 PMID:16935330 PMID:17080404 PMID:20726872 More...

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

increases activity
increases expression
multiple interactions

Colforsin results in increased activity of CYP19A1 protein
Colforsin results in increased expression of CYP19A1 mRNA
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]
RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein]
Colforsin results in increased expression of CYP19A1 mRNA; Colforsin results in increased expression of CYP19A1 protein

PMID:14691014 PMID:16357189 PMID:16935330 PMID:16996190 PMID:17080404 More...

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
affects expression

Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]
Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA]
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]

PMID:1849469 PMID:15710352 PMID:20726872

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]

PMID:1849469 PMID:15710352

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

Colforsin results in increased expression of CYP1B1 mRNA; Colforsin results in increased expression of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in decreased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
multiple interactions

Colforsin results in increased expression of CYP3A4 mRNA
[S-(1,2-dichlorovinyl)cysteine co-treated with Colforsin] results in increased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dopamine beta-hydroxylase

multiple interactions
increases expression

Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein]
Colforsin results in increased expression of DBH protein

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dopachrome tautomerase

increases expression

Colforsin results in increased expression of DCT mRNA; Colforsin results in increased expression of DCT protein

PMID:17460731 PMID:28601556

NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836

G

iodothyronine deiodinase 2

increases activity
multiple interactions
increases expression

Colforsin results in increased activity of DIO2 protein
Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]]

PMID:18420745 PMID:19036883

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

iodothyronine deiodinase 3

multiple interactions

Colforsin promotes the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA]

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

dynamin 1-like

multiple interactions
decreases expression

PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein]

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

dopamine receptor D2

multiple interactions

[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dynein light chain LC8-type 2

increases expression

Colforsin results in increased expression of DYNLL2 mRNA

NCBI chr10:72,767,035...72,785,824
Ensembl chr10:72,767,035...72,785,805

G

endothelin 1

multiple interactions

Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor

multiple interactions

[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

early growth response 1

decreases expression
multiple interactions

Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein
Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

eukaryotic translation initiation factor 2B subunit epsilon

increases expression

Colforsin results in increased expression of EIF2B5 mRNA

NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419

G

eukaryotic translation initiation factor 5A2

decreases expression

Colforsin results in decreased expression of EIF5A2 mRNA

NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087

G

epoxide hydrolase 1

affects expression
multiple interactions

Colforsin affects the expression of EPHX1 mRNA
Valproic Acid affects the reaction [Colforsin affects the expression of EPHX1 mRNA]

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

EGFR pathway substrate 8, signaling adaptor

decreases expression

Colforsin results in decreased expression of EPS8 mRNA

PMID:15313392 PMID:15967414

NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873

G

epiregulin

increases expression

Colforsin results in increased expression of EREG mRNA

PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endogenous retrovirus group FRD member 1, envelope

multiple interactions
increases expression
increases secretion

[Cadmium Chloride results in increased abundance of Cadmium] inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of ERVFRD-1 mRNA]
Colforsin results in increased expression of ERVFRD-1 mRNA; Colforsin results in increased expression of ERVFRD-1 protein
Colforsin results in increased secretion of ERVFRD-1 protein

PMID:24361490 PMID:29679653 PMID:31278978 PMID:33144174 PMID:35908931 More...

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

decreases expression

Colforsin results in decreased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
decreases expression

Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]
Colforsin results in decreased expression of ESR2 mRNA

PMID:20378682 PMID:31278978

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

estrogen related receptor, alpha

increases expression

Colforsin results in increased expression of ESRRA mRNA; Colforsin results in increased expression of ESRRA protein

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

ecotropic viral integration site 5

increases expression

Colforsin results in increased expression of EVI5 mRNA

NCBI chr14:1,875,601...2,021,678
Ensembl chr14:1,875,647...2,021,678

G

coagulation factor II, thrombin

multiple interactions

Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese]

NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486

G

coagulation factor II (thrombin) receptor

multiple interactions

[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

F2R like thrombin or trypsin receptor 3

multiple interactions

[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]

NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472

G

fatty acid desaturase 1

increases expression

Colforsin results in increased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid synthase

multiple interactions

[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

ferredoxin 1

multiple interactions
increases expression

ferulic acid analog promotes the reaction [Colforsin results in increased expression of FDX1 mRNA]

NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414

G

fibroblast growth factor 10

multiple interactions

Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein]

PMID:12533312 PMID:14975937

NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866

G

fibroblast growth factor 2

increases expression

Colforsin results in increased expression of FGF2 mRNA; Colforsin results in increased expression of FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 5

decreases expression

Colforsin results in decreased expression of FGF5 mRNA

NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997

G

fibroblast growth factor 8

increases activity

Colforsin results in increased activity of FGF8 protein

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

G

fibroblast growth factor 9

multiple interactions

FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

Fibroblast growth factor receptor 1

increases expression

Colforsin results in increased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 2

increases expression

Colforsin results in increased expression of FGFR2 mRNA

NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626

G

FKBP prolyl isomerase 5

multiple interactions

Colforsin promotes the reaction [Dexamethasone results in increased expression of FKBP5 mRNA]

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

Fms related receptor tyrosine kinase 1

increases expression

Colforsin results in increased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Colforsin results in increased expression of FOS protein
Dexamethasone inhibits the reaction [Colforsin results in increased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

Colforsin results in increased expression of FOSB mRNA; Colforsin results in increased expression of FOSB protein

PMID:11113530 PMID:17324382

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

follicle stimulating hormone subunit beta

increases expression

Colforsin results in increased expression of FSHB mRNA; Colforsin results in increased expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follistatin

multiple interactions

FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[Dexamethasone co-treated with Colforsin] results in increased expression of G6PC1 mRNA
Colforsin inhibits the reaction [Leflunomide results in increased expression of G6PC1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA]

PMID:18972406 PMID:30364229

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type A receptor subunit alpha 1

increases expression

Colforsin results in increased expression of GABRA1

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864

G

gamma-aminobutyric acid type A receptor subunit alpha6

decreases expression

Colforsin results in decreased expression of GABRA6

NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769

G

growth arrest specific 6

decreases expression

Colforsin results in decreased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

gastrin

multiple interactions
increases secretion

Calcium promotes the reaction [Colforsin results in increased secretion of GAST protein]; Nitrendipine inhibits the reaction [Colforsin results in increased secretion of GAST protein]
2',5'-dideoxyadenosine inhibits the reaction [Colforsin results in increased secretion of GAST protein]

PMID:9277405 PMID:19208342

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

glucagon

multiple interactions
increases secretion

Colforsin promotes the reaction [Pyruvic Acid results in increased secretion of GCG protein]
Colforsin results in increased secretion of GCG protein

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glial cells missing transcription factor 1

multiple interactions
increases expression
decreases expression

Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; Colforsin results in increased acetylation of and results in increased activity of GCM1 protein; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein]; trichostatin A promotes the reaction [Colforsin results in increased acetylation of and results in increased activity of GCM1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of GCM1 mRNA]
Colforsin results in decreased expression of GCM1 mRNA

PMID:16166624 PMID:31278978 PMID:37385477

NCBI chr 8:78,925,687...78,938,924
Ensembl chr 8:78,925,687...78,938,924

G

glial fibrillary acidic protein

decreases expression

Colforsin results in decreased expression of GFAP protein

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

growth hormone 1

increases secretion
multiple interactions

Colforsin results in increased secretion of GH1 protein
GH1 protein promotes the reaction [Colforsin results in increased metabolism of Lipids]

PMID:14981226 PMID:19952226

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

gap junction protein, alpha 1

multiple interactions
decreases expression

Valproic Acid inhibits the reaction [Colforsin results in decreased expression of GJA1 mRNA]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

GLI family zinc finger 1

decreases expression

Colforsin results in decreased expression of GLI1 mRNA; Colforsin results in decreased expression of GLI1 protein

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 2

multiple interactions

Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of GLI2 mRNA]

NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574

G

G protein subunit alpha i3

increases expression

Colforsin results in increased expression of GNAI3 mRNA

NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742

G

G protein-coupled bile acid receptor 1

multiple interactions

[Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Colforsin binds to and results in increased activity of GPBAR1 protein

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168

G

glutamate ionotropic receptor NMDA type subunit 1

increases phosphorylation
multiple interactions

Colforsin results in increased phosphorylation of GRIN1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein]

NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions
increases expression

N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein]
Colforsin results in increased expression of GRIN2B mRNA; Colforsin results in increased expression of GRIN2B protein

NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279

G

glycogen synthase kinase 3 beta

multiple interactions

Colforsin results in increased phosphorylation of and results in decreased activity of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

hepcidin antimicrobial peptide

affects expression
multiple interactions

Colforsin affects the expression of HAMP mRNA
Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

hydroxycarboxylic acid receptor 2

multiple interactions

[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

PMID:17124637 PMID:19223991

NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

Colforsin results in increased expression of HIF1A protein
[cobaltous chloride co-treated with Valproic Acid co-treated with Colforsin] results in increased expression of HIF1A protein; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HIF1A protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hexokinase 2

increases expression
multiple interactions

Colforsin results in increased expression of HK2 mRNA
cobaltous chloride inhibits the reaction [Valproic Acid inhibits the reaction [Colforsin results in increased expression of HK2 mRNA]]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HK2 mRNA]

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

3-hydroxy-3-methylglutaryl-CoA reductase

affects expression
increases expression
multiple interactions

Colforsin affects the expression of HMGCR mRNA
Colforsin results in increased expression of HMGCR mRNA
[Colforsin co-treated with Ketoconazole] results in decreased expression of HMGCR mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HMGCR mRNA; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HMGCR mRNA]

PMID:16751804 PMID:16935330 PMID:20726872 PMID:30825513 PMID:31557376

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA]

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

increases expression
multiple interactions

Colforsin results in increased expression of HMOX1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein]
Colforsin results in increased expression of HMOX1 mRNA; Colforsin results in increased expression of HMOX1 protein

PMID:15179140 PMID:16439612 PMID:19483313

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A1

multiple interactions

HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]

NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon]

NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997

G

histamine receptor H 2

multiple interactions

Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]

NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631

G

histamine receptor H3

multiple interactions

[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]

NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions
increases expression

Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in d